Can GLP-1 drugs like Ozempic improve survival in lung cancer patients?
GLP-1 receptor agonists cut the risk of lung cancer recurrence or death by roughly 59% in overweight patients, and appear to enhance how well immunotherapy works.
Quick Facts
What This Study Found
GLP-1 receptor agonist use was associated with a 59% reduction in the hazard of recurrence or death after lung cancer surgery (HR 0.41), and a 69% reduction in the hazard of progression when added to immunotherapy, in overweight and obese patients.
Key Numbers
- Surgical cohort: 1,177 patients, 71 GLP-1 users; recurrence HR 0.41 (95% CI 0.16-1.04, p=0.026)
- Immunotherapy cohort: 300 patients, 10 GLP-1 users; overall survival HR 0.41 (p=0.027); progression-free survival HR 0.31 (p=0.019)
- Mouse studies: tumor reduction in obese mice only
How They Did This
Propensity-score-matched retrospective analysis of two clinical cohorts (surgical resection n=1,177; immunotherapy n=300) plus mechanistic mouse model experiments in obese and normal-weight mice.
Why This Research Matters
Obesity worsens lung cancer prognosis, and immunotherapy is only partially effective. If GLP-1 drugs can reprogram the tumor immune microenvironment in obese patients, they could become an inexpensive add-on to existing cancer treatment—leveraging a medication millions already take.
The Bigger Picture
This adds to a growing body of evidence showing GLP-1 drugs reduce the incidence of several cancers. The obesity-restricted effect seen in mice suggests the mechanism is metabolic and immune—relevant specifically to obesity-driven tumor biology—rather than a direct anti-cancer drug effect.
What This Study Doesn't Tell Us
Small number of GLP-1 users in each cohort (especially only 10 in the immunotherapy group) limits statistical power. Retrospective design introduces potential unmeasured confounders. Mouse results may not translate directly to humans. Obesity definition varies.
Questions This Raises
- ?Would prospective randomized trials confirm GLP-1 drugs as a cancer treatment adjunct?
- ?Do non-obese lung cancer patients receive any benefit from GLP-1 drugs?
- ?Which specific GLP-1 drug (or dose) produces the strongest immune modulation in tumors?
Trust & Context
- Key Stat:
- 59% Reduction in hazard of lung cancer recurrence or death after surgery for overweight/obese patients on GLP-1 drugs (HR 0.41)
- Evidence Grade:
- Rated moderate because both clinical arms are retrospective and involve very small GLP-1-user subgroups; propensity matching reduces but does not eliminate confounding.
- Study Age:
- Published in 2025 in JCI Insight; clinical data drawn from existing hospital records across multiple time periods.
- Original Title:
- Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control.
- Published In:
- JCI insight, 10(19) (2025)
- Authors:
- Pachimatla, Akhil Goud, Fitzgerald, Bailey, Ogidigo, Joyce, Bhatia, Meera, Smith, Randall J, Ratnakaram, Kalyan, Kalvapudi, Sukumar, Vedire, Yeshwanth, Washington, Deschana, Vethanayagam Rr, Robert, Hsiao, Hua-Hsin, Rosario, Spencer, Sanghvi, Viraj R, Barbi, Joseph, Yendamuri, Sai
- Database ID:
- RPEP-12908
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Does this mean GLP-1 drugs treat cancer?
Not directly. The evidence suggests they improve outcomes as an add-on, likely by reducing obesity-related immune suppression in tumors—not by killing cancer cells themselves.
Should I start a GLP-1 drug to prevent lung cancer recurrence?
This study is preliminary and retrospective. Discuss with your oncologist before making any medication changes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12908APA
Pachimatla, Akhil Goud; Fitzgerald, Bailey; Ogidigo, Joyce; Bhatia, Meera; Smith, Randall J; Ratnakaram, Kalyan; Kalvapudi, Sukumar; Vedire, Yeshwanth; Washington, Deschana; Vethanayagam Rr, Robert; Hsiao, Hua-Hsin; Rosario, Spencer; Sanghvi, Viraj R; Barbi, Joseph; Yendamuri, Sai. (2025). Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control.. JCI insight, 10(19). https://doi.org/10.1172/jci.insight.195484
MLA
Pachimatla, Akhil Goud, et al. "Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control.." JCI insight, 2025. https://doi.org/10.1172/jci.insight.195484
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like peptide-1 receptor agonism improves lung cance..." RPEP-12908. Retrieved from https://rethinkpeptides.com/research/pachimatla-2025-glucagonlike-peptide1-receptor-agonism
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.